carmustine has been researched along with Pancytopenia in 3 studies
Carmustine: A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
carmustine : A member of the class of N-nitrosoureas that is 1,3-bis(2-chloroethyl)urea in which one of the nitrogens is substituted by a nitroso group.
Pancytopenia: Deficiency of all three cell elements of the blood, erythrocytes, leukocytes and platelets.
| Excerpt | Relevance | Reference |
|---|---|---|
| "With the eventual goal of reducing relapse and thus improving overall survival in selected lymphoma patients, a Phase I study was performed using the cytoprotectant amifostine to permit safe dose-augmentation of melphalan in the carmustine (BCNU), etoposide, cytarabine (arabinosylcytosine), and melphalan (BEAM) regimen before autologous hematopoietic stem cell transplantation." | 5.15 | A Phase I trial: dose escalation of melphalan in the "BEAM" regimen using amifostine cytoprotection. ( Abboud, CN; Becker, MW; Bernstein, SH; Constine, LS; Friedberg, JW; Ifthikharuddin, JJ; Liesveld, JL; Loughner, JE; Milner, LA; Phillips, GL; Vesole, DH, 2011) |
| "A 42-year-old male patient with a history of occupational exposure to benzene presented with pancytopenia." | 3.69 | t(9;13)(q34;q12) chromosomal translocation persisting 4 years post autologous bone marrow transplantation for secondary AML despite morphological remission. ( Mahendra, P; Marcus, RE; Nacheva, E; Richards, EM; Sinclair, P, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (66.67) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Phillips, GL | 1 |
| Bernstein, SH | 1 |
| Liesveld, JL | 1 |
| Abboud, CN | 1 |
| Becker, MW | 1 |
| Constine, LS | 1 |
| Ifthikharuddin, JJ | 1 |
| Loughner, JE | 1 |
| Milner, LA | 1 |
| Vesole, DH | 1 |
| Friedberg, JW | 1 |
| Bastion, Y | 1 |
| Brice, P | 1 |
| Haioun, C | 1 |
| Sonet, A | 1 |
| Salles, G | 1 |
| Marolleau, JP | 1 |
| Espinouse, D | 1 |
| Reyes, F | 1 |
| Gisselbrecht, C | 1 |
| Coiffier, B | 1 |
| Mahendra, P | 1 |
| Richards, EM | 1 |
| Sinclair, P | 1 |
| Nacheva, E | 1 |
| Marcus, RE | 1 |
1 trial available for carmustine and Pancytopenia
| Article | Year |
|---|---|
A Phase I trial: dose escalation of melphalan in the "BEAM" regimen using amifostine cytoprotection.
Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Atrial Fibrillation; Carmus | 2011 |
2 other studies available for carmustine and Pancytopenia
| Article | Year |
|---|---|
Intensive therapy with peripheral blood progenitor cell transplantation in 60 patients with poor-prognosis follicular lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cyclophospham | 1995 |
t(9;13)(q34;q12) chromosomal translocation persisting 4 years post autologous bone marrow transplantation for secondary AML despite morphological remission.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Benzene; Bone Marrow; Bone Mar | 1996 |